Amicus Therapeutics Announces Participation in SSIEM 2024 Annual Symposium

Fabry disease:

Summary Title: FollowME Fabry Pathfinders registry: patient-reported outcomes in a cohort of patients treated with migalastat for at least two years (Poster #21180)

• Presenter: Aleš Linhart, D.Sc., Charles University and General University Hospital in Prague, Prague, Czech Republic
• Poster session: Wednesday September 4, 6:15 PM – 8:15 PM WET
• Location: Poster room, Rosa Mota pavilion

Summary Title: Quality of life in migalastat-treated adolescents with Fabry disease: results from the ASPIRE study and open-label extension (Poster #21202)

• Presenter: Amarilis Sanchez-Valle, MD, University of South Florida Health, Tampa, USA
• Poster session: Wednesday September 4, 6:15 PM – 8:15 PM WET
• Location: Poster room, Rosa Mota pavilion

Summary Title: Research into the journey of patients with Fabry disease in Poland (Poster #20789)

• Presenter: Anna Moskal, Association of Families with Fabry Disease, Wroclaw, Poland
• Poster session: Wednesday September 4, 6:15 PM – 8:15 PM WET
• Location: Poster room, Rosa Mota pavilion

Pompe disease:

Summary Title: Post-baseline results from the UK Early Access to Medicines Scheme registry for cipaglucosidase alfa plus miglustat in late-onset Pompe disease (Poster #20863)

• Presenter: Elaine Murphy, MD, University College London Hospitals, London, UK
• Poster session: Wednesday September 4, 6:15 PM – 8:15 PM WET
• Guided poster walk: Thursday September 5, 12:10 – 13:40 WET
• Location: Poster room, Rosa Mota pavilion

Summary Title: Miglustat: a first-in-class enzyme stabilizer for late-onset Pompe disease (Poster #20873)

• Presenter: Mark Roberts, MD, Salford Royal NHS Foundation Trust, Greater Manchester Neurosciences Centre, Manchester, UK
• Poster session: Wednesday September 4, 6:15 PM – 8:15 PM WET
• Location: Poster room, Rosa Mota pavilion

For more information about the SSIEM 2024 Annual Symposium, visit ssiem2024.org.

About Amicus Therapeutics
Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-focused biotechnology company focused on discovering, developing and delivering novel, high-quality medicines for people with rare diseases. With an unmatched focus on patients, Amicus Therapeutics is committed to advancing and expanding a pipeline of advanced, first- or best-in-class medicines for rare diseases. For more information, please visit the company’s website at www.amicusrx.com and follow us on X and LinkedIn.

CONTACTS:

Investors:
Amicus Therapeutica
Andrew Faughnan
Vice Chairman, Investor Relations
[email protected]
(609) 662-3809

Media:
Amicus Therapeutica
Diana Moore
Head of Global Corporate Communications
[email protected]
(609) 662-5079

FOLD–G

Diskutieren Sie über die entaltenen Werte